Bausch Health Companies (BHC) to Release Quarterly Earnings on Wednesday

Bausch Health Companies (NYSE:BHC) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 19th. Analysts expect Bausch Health Companies to post earnings of $1.65 per share and revenue of $2.51 billion for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Bausch Health Companies Price Performance

Shares of BHC opened at $6.38 on Wednesday. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -13.29, a P/E/G ratio of 0.34 and a beta of 0.68. The business’s 50-day moving average is $7.59 and its 200-day moving average is $7.46. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BHC. Jefferies Financial Group reiterated a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Royal Bank of Canada reduced their price objective on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. Finally, Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Bausch Health Companies has a consensus rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.